Zacks Research Upgrades Telomir Pharmaceuticals (NASDAQ:TELO) to Hold

Telomir Pharmaceuticals (NASDAQ:TELO) was upgraded by analysts at Zacks Research to a “hold” rating in a research note issued to investors on Wednesday,Zacks.com reports.

TELO has been the subject of a number of other reports. Weiss Ratings restated a “sell (e+)” rating on shares of Telomir Pharmaceuticals in a research note on Thursday, January 22nd. Rodman & Renshaw assumed coverage on shares of Telomir Pharmaceuticals in a research report on Tuesday, January 13th. They set a “buy” rating on the stock. Finally, Wall Street Zen upgraded shares of Telomir Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, February 21st. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Telomir Pharmaceuticals presently has an average rating of “Hold”.

Telomir Pharmaceuticals Stock Performance

Shares of NASDAQ TELO opened at $1.31 on Wednesday. The business’s 50-day simple moving average is $1.26 and its 200-day simple moving average is $1.36. The firm has a market cap of $44.97 million, a price-to-earnings ratio of -3.96 and a beta of -0.66. Telomir Pharmaceuticals has a 52 week low of $1.05 and a 52 week high of $4.81.

Telomir Pharmaceuticals (NASDAQ:TELO) last released its earnings results on Tuesday, March 17th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.01. As a group, equities research analysts forecast that Telomir Pharmaceuticals will post -0.4 earnings per share for the current year.

Institutional Trading of Telomir Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in TELO. Geode Capital Management LLC lifted its stake in Telomir Pharmaceuticals by 14.0% in the fourth quarter. Geode Capital Management LLC now owns 223,549 shares of the company’s stock valued at $297,000 after buying an additional 27,519 shares in the last quarter. Marshall Wace LLP acquired a new position in Telomir Pharmaceuticals in the 2nd quarter valued at about $95,000. Raymond James Financial Inc. raised its holdings in Telomir Pharmaceuticals by 4,101.9% in the 3rd quarter. Raymond James Financial Inc. now owns 75,340 shares of the company’s stock valued at $105,000 after acquiring an additional 73,547 shares during the period. Jane Street Group LLC bought a new stake in shares of Telomir Pharmaceuticals during the second quarter worth approximately $62,000. Finally, XTX Topco Ltd acquired a new position in shares of Telomir Pharmaceuticals in the fourth quarter valued at approximately $53,000.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc (NASDAQ: TELO) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapies for cardiometabolic and fibrotic diseases. Leveraging a proprietary target discovery platform, the company aims to identify and modulate key biological pathways implicated in tissue fibrosis, inflammation and metabolic dysregulation. Its research strategy centers on oral agents intended to address high-unmet-need conditions such as nonalcoholic steatohepatitis (NASH) and systemic fibrotic disorders, where existing treatment options are limited.

The company’s lead development candidate is an oral inhibitor currently in early-phase clinical trials that targets growth factors involved in fibrotic tissue remodeling.